IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even after curative treatment for hepatitis C virus-related hepatocellular carcinoma

[Guest guest]

http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2893.2011.01468.x/abstract

IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even

after curative treatment for hepatitis C virus-related hepatocellular carcinoma

T. Kawaoka1,2, H. Aikata1, S. Takaki1, A. Hiramatsu1, K. Waki1, N. Hiraga1, D.

Miki1,2, M. Tsuge1, M. Imamura1, Y. Kawakami1, S. Takahashi1, H. Ochi1,2, H.

Tashiro3, H. Ohdan3, K. ma1,2Article first published online: 23 MAY 2011

DOI: 10.1111/j.1365-2893.2011.01468.x

© 2011 Blackwell Publishing Ltd

Issue

Journal of Viral Hepatitis

Early View (Online Version of Record published before inclusion in an issue)

Summary.  The present study was designed to determine the predictive factors

for the viral response to pegylated interferon-alpha plus ribavirin combination

therapy (PEGIFN/RBV) administered after curative treatment for hepatitis C virus

(HCV)-related hepatocellular carcinoma (HCC). The study group was 78 patients

treated between January 2005 and January 2009. The sustained viral response

(SVR) rate was 25.8% (15/58) in patients infected with HCV-genotype 1 and 55.0%

(11/20) in those with genotype 2. Among the 78 patients, 32 (41.0%) could not

complete the treatment protocol, and this was because of HCC recurrence in 17

(53%) of them. Multivariate analysis identified partial early viral response

(pEVR) as the only independent determinant of SVR [odds ratio (OR) 14.73, P =

0.013] for patients with genotype 1. Multivariate analysis identified male

gender (OR 8.72, P = 0.001) and interleukin-28B (IL-28B) genotype (rs8099917) TT

(OR 7.93, P = 0.007) as independent predictors of pEVR. Multivariate analysis

also identified IL-28B genotype GG+TG (OR 14.1, P = 0.021) and α-fetoprotein

>30 (OR 5.4, P = 0.031) as independent predictors of null response. Patients

with SVR showed a better survival rate than those without SVR (P = 0.034). The

second HCC recurrence rate tended to be lower in patients with SVR than in those

without SVR (P = 0.054). With regard to the prognosis of patients with SVR, it

is desirable to achieve SVR with interferon therapy even when administered after

HCC treatment. IL-28B genotype is a potentially useful marker for the response

to PEGIFN/RBV therapy administered after curative treatment of HCV-related HCC.

[Guest guest]

http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2893.2011.01468.x/abstract

IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even

after curative treatment for hepatitis C virus-related hepatocellular carcinoma

T. Kawaoka1,2, H. Aikata1, S. Takaki1, A. Hiramatsu1, K. Waki1, N. Hiraga1, D.

Miki1,2, M. Tsuge1, M. Imamura1, Y. Kawakami1, S. Takahashi1, H. Ochi1,2, H.

Tashiro3, H. Ohdan3, K. ma1,2Article first published online: 23 MAY 2011

DOI: 10.1111/j.1365-2893.2011.01468.x

© 2011 Blackwell Publishing Ltd

Issue

Journal of Viral Hepatitis

Early View (Online Version of Record published before inclusion in an issue)

Summary.  The present study was designed to determine the predictive factors

for the viral response to pegylated interferon-alpha plus ribavirin combination

therapy (PEGIFN/RBV) administered after curative treatment for hepatitis C virus

(HCV)-related hepatocellular carcinoma (HCC). The study group was 78 patients

treated between January 2005 and January 2009. The sustained viral response

(SVR) rate was 25.8% (15/58) in patients infected with HCV-genotype 1 and 55.0%

(11/20) in those with genotype 2. Among the 78 patients, 32 (41.0%) could not

complete the treatment protocol, and this was because of HCC recurrence in 17

(53%) of them. Multivariate analysis identified partial early viral response

(pEVR) as the only independent determinant of SVR [odds ratio (OR) 14.73, P =

0.013] for patients with genotype 1. Multivariate analysis identified male

gender (OR 8.72, P = 0.001) and interleukin-28B (IL-28B) genotype (rs8099917) TT

(OR 7.93, P = 0.007) as independent predictors of pEVR. Multivariate analysis

also identified IL-28B genotype GG+TG (OR 14.1, P = 0.021) and α-fetoprotein

>30 (OR 5.4, P = 0.031) as independent predictors of null response. Patients

with SVR showed a better survival rate than those without SVR (P = 0.034). The

second HCC recurrence rate tended to be lower in patients with SVR than in those

without SVR (P = 0.054). With regard to the prognosis of patients with SVR, it

is desirable to achieve SVR with interferon therapy even when administered after

HCC treatment. IL-28B genotype is a potentially useful marker for the response

to PEGIFN/RBV therapy administered after curative treatment of HCV-related HCC.